Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC — Investor Relations & Filings

Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country US United States of America
Listing US SCYX

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
8-K
Share Issue/Capital Change Classification · 90% confidence The document is a Form 8-K current report filed with the SEC by SCYNEXIS, Inc. It describes an amendment to the company’s certificate of incorporation effecting a one-for-eight reverse stock split of common stock and a reduction in authorized shares. This is clearly a corporate action relating to a stock split (capital change), matching the ‘Share Issue/Capital Change’ category. Therefore, the correct classification is SHA.
2026-05-29 English
8-K
Regulatory Filings
2026-05-22 English
10-Q - SCYNEXIS INC (0001178253) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
424B3 - SCYNEXIS INC (0001178253) (Filer)
Regulatory Filings
2026-05-08 English
S-3 - SCYNEXIS INC (0001178253) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by SCYNEXIS, Inc. It is a registration statement under the Securities Act of 1933 for the resale of common stock by selling stockholders. The document includes a prospectus for the offering of shares, details about the selling stockholders, risk factors, and other related information. This type of filing is related to capital raising and securities registration rather than financial reporting, management changes, or other categories. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains detailed offering information, not just an announcement or a brief notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2026-05-01 English
DEF 14A - SCYNEXIS INC (0001178253) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.